News

Some 25% of Cushing’s disease patients — or 1 in every 4 — will develop Nelson’s syndrome (NS) after surgery to remove both adrenal glands, while around 1 in every 5 will need pituitary-specific treatment, a study found. Lifelong follow-up is also needed for patients who undergo double adrenal gland…

Ahead of this year’s Rare Disease Week on Capitol Hill, held virtually July 14–22, the EveryLife Foundation will award grants to top advocates of rare disease organizations who participate in the week’s pre-events. The top 50 point-earners will be eligible to win $1,000 to $5,000in  grants, totaling up…

Symptoms of psoriasis vulgaris, an autoimmune disease that mainly affects the skin, eased in a man with cyclic Cushing’s disease during a short episode of hypercortisolemia, a period marked by cortisol levels rising above healthy limits, according to a case study.

Xeris Pharmaceuticals and Strongbridge Biopharma have entered an agreement in which Xeris will acquire Strongbridge, forming a new entity called Xeris Biopharma Holdings. Following the transaction, Xeris also will acquire Strongbridge’s pipeline, which includes Recorlev (levoketoconazole), an investigational treatment for endogenous Cushing’s syndrome. “Strongbridge’s attractive rare…

Sparrow Pharmaceuticals is planning to launch a Phase 2 clinical trial to assess the safety and effectiveness of its investigational, lead small molecule HSD-1 inhibitor, SPI-62, in people with Cushing’s syndrome. The trial is expected to open later this year, and it specifically will enroll people with ACTH-dependent Cushing’s…

Metopirone (metyrapone) safely and successfully maintained lower levels of urinary cortisol over nine months in adults with endogenous Cushing’s syndrome, according to data from the six-month extension of the PROMPT trial.  Treatment with the HRA Pharma Rare Diseases…

For people with Cushing’s disease whose pituitary tumor cannot be identified, removal of one-third of the pituitary gland followed by multidisciplinary treatment and care can lead to favorable outcomes, a small study suggests. The study, “Lateral one-third gland resection in Cushing patients with failed adenoma identification…

The U.S. Food and Drug Administration (FDA) is reviewing an application from Strongbridge Biopharma seeking the approval of Recorlev (levoketoconazole) for the treatment of endogenous Cushing’s syndrome. A final decision from the FDA is expected by Jan. 1, 2022 — meaning that Recorlev’s approval request will follow the…

The case of an elderly woman who developed shingles triggered by subclinical Cushing’s disease, and later died from sudden cardiac arrest, underscores the importance of closely monitoring immune responses in patients showing signs of that disorder. Her case was described in the…

Chronic insomnia can be a sign of Cushing’s syndrome, and doctors need be aware of this possibility, according to a case report of a woman diagnosed with Cushing’s shortly after seeking help for her insomnia. This case also emphasized the usefulness of the dexamethasone suppression test in identifying the specific…